2,737 reports of this reaction
3.4% of all ARIPIPRAZOLE ORALLY DISINTEGRATING reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for ARIPIPRAZOLE ORALLY DISINTEGRATING, manufactured by Accord Healthcare, Inc.. There are 2,737 FDA adverse event reports linking ARIPIPRAZOLE ORALLY DISINTEGRATING to OFF LABEL USE. This represents approximately 3.4% of all 79,930 adverse event reports for this drug.
Patients taking ARIPIPRAZOLE ORALLY DISINTEGRATING who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among ARIPIPRAZOLE ORALLY DISINTEGRATING users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for ARIPIPRAZOLE ORALLY DISINTEGRATING:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 2,737 FDA reports for ARIPIPRAZOLE ORALLY DISINTEGRATING. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.4% of all adverse event reports for ARIPIPRAZOLE ORALLY DISINTEGRATING, making it one of the most commonly reported side effect.
If you experience off label use while taking ARIPIPRAZOLE ORALLY DISINTEGRATING, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.